The relevance of the individual genetic background for the toxicokinetics of two significant neurodevelopmental toxicants: Mercury and lead

Mutation Research - Reviews in Mutation Research

Volumn 705, Issue 2, 2010, Pages 130-140

  Gundacker, Claudia ^a   Gencik, Martin ^b   Hengstschläger, Markus ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Praxis fur Humangenetik   (Austria)

Author keywords

Genotype phenotype association; Individual susceptibility; Lead; Mercury; Toxicogenetics

Indexed keywords

ABC TRANSPORTER; GLUTAMATE CYSTEINE LIGASE; GLUTATHIONE; GLUTATHIONE TRANSFERASE A1; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE P1; GLUTATHIONE TRANSFERASE T1; LAT PROTEIN; LEAD; MERCURY; METALLOTHIONEIN I; METALLOTHIONEIN II; METALLOTHIONEIN III; METHYLMERCURY; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; NATURAL RESISTANCE ASSOCIATED MACROPHAGE PROTEIN 2; ORGANIC ANION TRANSPORTER 1; ORGANIC ANION TRANSPORTER 3; PORPHOBILINOGEN SYNTHASE; VITAMIN D RECEPTOR;

BEHAVIOR DISORDER; BILE FLOW; BIOTRANSFORMATION; BLINDNESS; BLOOD; BLOOD BRAIN BARRIER; BONE; BRAIN DEVELOPMENT; CELL MEMBRANE; CENTRAL NERVOUS SYSTEM; CEREBRAL PALSY; DEVELOPMENTAL DISORDER; ERYTHROCYTE; GASTROINTESTINAL ABSORPTION; GASTROINTESTINAL TRACT; GENE EXPRESSION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SUSCEPTIBILITY; HAPLOTYPE MAP; HUMAN; INGESTION; INHALATION; LIVE BIRTH; MENTAL DEFICIENCY; MERCURIALISM; MINAMATA DISEASE; NEUROTOXICITY; OCCUPATIONAL EXPOSURE; OXIDATIVE STRESS; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN FUNCTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SOFT TISSUE; TOXICOKINETICS; URINARY EXCRETION; DRUG EFFECTS; EMBRYOLOGY; GENE SILENCING; NERVOUS SYSTEM; PHARMACOGENETICS; TOXICITY;

BIOTRANSFORMATION; GENE EXPRESSION; GENE KNOCKDOWN TECHNIQUES; HUMANS; LEAD; MERCURY; NERVOUS SYSTEM; PHARMACOGENETICS; POLYMORPHISM, GENETIC;

EID: 77956188782     PISSN: 13835742     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mrrev.2010.06.003     Document Type: Review

References (150)

1. Grandjean P., Landrigan P. Developmental neurotoxicity of industrial chemicals. Lancet 2006, 368:2167-2178.
2. Rice D., Barone S. Critical periods of vulnerability for the developing nervous system: evidence from humans and animal models. Environ. Health Perspect. 2000, 108:511-533.
3. National Research Council Scientific Frontiers in Developmental Toxicology and Risk Assessment 2000, National Academy Press, Washington, DC.
4. Nordberg M., Duffus J.H., Templeton D.M. Glossary of terms used in toxicokinetics (IUPAC Recommendations 2003). Pure Appl. Chem. 2004, 76:1033-1082.
5. Crespo-López M.E., Macêdo G.L., Pereira S.I.D., Arrifano G.P.F., Picanço-Diniz D.L.W., Nascimento J.L.M., Herculano A.M. Mercury and human genotoxicity: critical considerations and possible molecular mechanisms. Pharmacol. Res. 2009, 60:212-220.
6. Chen Z., Lou J., Chen S., Zheng W., Wu W., Jin L., Deng H., He J. Evaluating the genotoxic effects of workers exposed to lead using micronucleus assay, comet assay and TCR gene mutation test. Toxicology 2006, 223:219-226.
7. Wright R.O., Baccarelli A. Metals and neurotoxicology. J. Nutr. 2007, 137:2809-2813.
8. Zawia N.H., Lahiri D.K., Cardozo-Pelaez F. Epigenetics, oxidative stress, and Alzheimer disease. Free Radic. Biol. Med. 2009, 46:1241-1249.
9. M.J. LeBaron, R.J. Rasoulpour, J. Klapacz, R.G. Ellis-Hutchings, H.M. Hollnagel, B.B. Gollapudi, Epigenetics and chemical safety assessment, Mutat. Res.-Rev. Mutat., in press, corrected proof.
10. Pilsner J.R., Hu H., Ettinger A., Sánchez B.N., Wright R.O., Cantonwine D., Lazarus A., Lamadrid-Figueroa H., Mercado-García A., Téllez-Rojo M.M., Hernández-Avila M. Influence of prenatal lead exposure on genomic methylation of cord blood DNA. Environ. Health Perspect. 2009, 117:1466-1471.
11. Björklund O., Kahlström J., Salmi P., Ögren S.O., Vahter M., Chen J.-F., Fredholm B.B., Dare E. The effects of methylmercury on motor activity are sex- and age-dependent, and modulated by genetic deletion of adenosine receptors and caffeine administration. Toxicology 2007, 241:119-133.
12. Heyer N.J., Echeverria D., Bittner A.C., Farin F.M., Garabedian C.C., Woods J.S. Chronic low-level mercury exposure, BDNF polymorphism, and associations with self-reported symptoms and mood. Toxicol. Sci. 2004, 81:354-363.
13. Clarkson T.W. The three modern faces of mercury. Environ. Health Perspect. 2002, 110:11-23.
14. US EPA (2009), Lead in paint, dust, and soil. http://www.epa.gov/lead/.
15. Brown M.J., Hu H., Gonzales-Cossio T., Peterson K.E., Sanin L.H., de Luz Kageyama M., Palazuelos E., Aro A., Schnaas L., Hernandez-Avila M. Determinants of bone and blood lead concentrations in the early postpartum period. Occup. Environ. Med. 2000, 57:535-541.
16. Ballatori N. Glutathione mercaptides as transport forms of metals. Adv. Pharmacol. 1994, 27:271-298.
17. Bridges C.C., Zalups R.K. Molecular and ionic mimicry and the transport of toxic metals. Toxicol. Appl. Pharm. 2005, 204:274-308.
18. Atchison W., Hare M. Mechanisms of methylmercury-induced neurotoxicity. FASEB J. 1994, 8:622-629.
19. Castoldi A.F., Coccini T., Ceccatelli S., Manzo L. Neurotoxicity and molecular effects of methylmercury. Brain Res. Bull. 2001, 55:197-203.
20. Li Z., Dong T., Pröschel C., Noble M. Chemically diverse toxicants converge on Fyn and c-Cbl to disrupt precursor cell function. PLoS Biol. 2007, 5:e35.
21. White L.D., Cory-Slechta D.A., Gilbert M.E., Tiffany-Castiglioni E., Zawia N.H., Virgolini M., Rossi-George A., Lasley S.M., Qian Y.C., Basha M.R. New and evolving concepts in the neurotoxicology of lead. Toxicol. Appl. Pharm. 2007, 225:1-27.
22. Clarkson T.W., Magos L. The toxicology of mercury and its chemical compounds. Crit. Rev. Toxicol. 2006, 36:609-662.
23. Budtz-Jorgensen E., Grandjean P., Keiding N., White R.F., Weihe P. Benchmark dose calculations of methylmercury-associated neurobehavioural deficits. Toxicol. Lett. 2000, 112-113:193-199.
24. Cohen J.T., Bellinger D.C., Shaywitz B.A. A quantitative analysis of prenatal methyl mercury exposure and cognitive development. Am. J. Prev. Med. 2005, 29. 353-353.e24.
25. Clarkson T.W., Strain J.J. Nutritional factors may modify the toxic action of methyl mercury in fish-eating populations. J. Nutr. 2003, 133:1539S-1543S.
26. Lanphear B.P., Hornung R., Khoury J., Yolton K., Baghurst P., Bellinger D.C., Canfield R.L., Dietrich K.N., Bornschein R., Greene T., Rothenberg S.J., Needleman H.L., Schnaas L., Wasserman G., Graziano J., Roberts R. Low-level environmental lead exposure and children's intellectual function: an international pooled analysis. Environ. Health Perspect. 2005, 113:894-899.
27. Jusko T.A., Henderson C.R., Lanphear B.P., Cory-Slechta D.A., Parsons P.J., Canfield R.L. Blood lead concentrations <10μg/dL and child intelligence at 6 years of age. Environ. Health Perspect. 2008, 116:243-248.
28. Miranda M.L., Kim D., Overstreet Galeano M.A., Paul C.J., Hull A.P., Morgan S.P. The relationship between early childhood blood lead levels and performance on end-of-grade tests. Environ. Health Perspect. 2007, 115:1242-1247.
29. Jedrychowski W., Perera F., Jankowski J., Mrozek-Budzyn D., Mroz E., Flak E., Edwards S., Skarupa A., Lisowska-Miszczyk I. Gender specific differences in neurodevelopmental effects of prenatal exposure to very low-lead levels: the prospective cohort study in three-year olds. Early Hum. Dev. 2009, 85:503-510.
30. Gilbert S.G., Weiss B. A rationale for lowering the blood lead action level from 10 to 2μg/dL. NeuroToxicology 2006, 27:693-701.
31. Wigle D.T., Lanphear B.P. Human health risks from low-level environmental exposures: no apparent safety thresholds. PLoS Med. 2005, 2:e350.
32. Gochfeld M. Factors influencing susceptibility to metals. Environ. Health Perspect. 1997, 105:817-822.
33. Ramensky V., Bork P., Sunyaev S. Human non-synonymous SNPs: server and survey. Nucl. Acids Res. 2002, 30:3894-3900.
34. Xu Z., Kaplan N.L., Taylor J.A. Tag SNP selection for candidate gene association studies using HapMap and gene resequencing data. Eur. J. Hum. Genet. 2007, 15:1063-1070.
35. Heggland I., Kaur P., Syversen T. Uptake and efflux of methylmercury in vitro: comparison of transport mechanisms in C6, B35 and RBE4 cells. Toxicol. In Vitro 2009, 23:1020-1027.
36. del Amo E.M., Urtti A., Yliperttula M. Pharmacokinetic role of l-type amino acid transporters LAT1 and LAT2. Eur. J. Pharm. Sci. 2008, 35:161-174.
37. Hoffmeyer R.E., Singh S.P., Doonan C.J., Ross A.R.S., Hughes R.J., Pickering I.J., George G.N. Molecular mimicry in mercury toxicology. Chem. Res. Toxicol. 2006, 19:753-759.
38. Kerper L.E., Ballatori N., Clarkson T.W. Methylmercury transport across the blood-brain barrier by an amino acid carrier. Am. J. Physiol. Regul. Integr. Comp. Physiol. 1992, 262:761-765.
39. Kajiwara Y., Yasutake A., Adachi T., Hirayama K. Methylmercury transport across the placenta via neutral amino acid carrier. Arch. Toxicol. 1996, 70:310-314.
40. Simmons-Willis T.A., Koh A.S., Clarkson T.W., Ballatori N. Transport of a neurotoxicant by molecular mimicry: the methylmercury-l-cysteine complex is a substrate for human l-type large neutral amino acid transporter (LAT) 1 and LAT2. Biochem. J. 2002, 367:239-246.
41. Tsumura H., Suzuki N., Saito H. The targeted disruption of the CD98 gene results in embryonic lethality. Biochem. Biophys. Res. Commun. 2003, 308:847-851.
42. Nicklin P., Bergman P., Zhang B., Triantafellow E., Wang H., Nyfeler B., Yang H., Hild M., Kung C., Wilson C. Bidirectional transport of amino acids regulates mTOR and autophagy. Cell 2009, 136:521-534.
43. Yin Z., Jiang H., Syversen T., Rocha J.B.T., Farina M., Aschner M. The methylmercury-l-cysteine conjugate is a substrate for the l-type large neutral amino acid transporter. J. Neurochem. 2008, 107:1083-1090.
44. Boado R.J., Li J.Y., Pardridge W.M. Site-directed mutagenesis of rabbit LAT1 at amino acids 219 and 234. J. Neurochem. 2003, 84:1322-1331.
45. Boado R.J., Li J.Y., Wise P., Pardridge W.M. Human LAT1 single nucleotide polymorphism N230K does not alter phenylalanine transport. Mol. Genet. Metab. 2004, 83:306-311.
46. Boado R.J., Li J.Y., Chu C., Ogoshi F., Wise P., Pardridge W.M. Site-directed mutagenesis of cysteine residues of large neutral amino acid transporter LAT1. BBA: Biomembranes 2005, 1715:104-110.
47. Kühne A., Kaiser R., Schirmer M., Heider U., Muhlke S., Niere W., Overbeck T., Hohloch K., Trümper L., Sezer O., Brockmöller J. Genetic polymorphisms in the amino acid transporters LAT1 and LAT2 in relation to the pharmacokinetics and side effects of melphalan. Pharmacogenet. Genom. 2007, 17:505-517.
48. Srimaroeng C., Perry J.L., Pritchard J.B. Physiology, structure, and regulation of the cloned organic anion transporters. Xenobiotica 2008, 38:889-935.
49. Aslamkhan A.G., Han Y.H., Yang X.P., Zalups R.K., Pritchard J.B. Human renal organic anion transporter 1-dependent uptake and toxicity of mercuric-thiol conjugates in madin-darby canine kidney cells. Mol. Pharmacol. 2003, 63:590-596.
50. Eraly S.A., Bush K.T., Sampogna R.V., Bhatnagar V., Nigam S.K. The molecular pharmacology of organic anion transporters: from DNA to FDA?. Mol. Pharmacol. 2004, 65:479-487.
51. Sweet D.H., Miller D.S., Pritchard J.B., Fujiwara Y., Beier D.R., Nigam S.K. Impaired organic anion transport in kidney and choroid plexus of organic anion transporter 3 (Oat3 (Slc22a8)) knockout mice. J. Biol. Chem. 2002, 277:26934-26943.
52. Fujita T., Brown C., Carlson E.J., Taylor T., De La Cruz M., Johns S.J., Stryke D., Kawamoto M., Fujita K., Castro R., Chen C.W., Lin E.T., Brett C.M., Burchard E.G., Ferrin T.E., Huang C.C., Leabman M.K., Giacomini K.M. Functional analysis of polymorphisms in the organic anion transporter SLC22A6 (OAT1). Pharmacogenet. Genom. 2005, 15:201-209.
53. Bleasby K., Hall L.A., Perry J.L., Mohrenweiser H.W., Pritchard J.B. Functional consequences of single nucleotide polymorphisms in the human organic anion transporter hOAT1 (SLC22A6). J. Pharmacol. Exp. Ther. 2005, 314:923-931.
54. Nishizato Y., Ieiri I., Suzuki H., Kimura M., Kawabata K., Hirota T., Takane H., Irie S., Kusuhara H., Urasaki Y., Urae A., Higuchi S., Otsubo K., Sugiyama Y. Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin. Pharmacol. Ther. 2003, 73:554-565.
55. Erdman A.R., Mangravite L.M., Urban T.J., Lagpacan L.L., Castro R.A., de la Cruz M., Chan W., Huang C.C., Johns S.J., Kawamoto M., Stryke D., Taylor T.R., Carlson E.J., Ferrin T.E., Brett C.M., Burchard E.G., Giacomini K.M. The human organic anion transporter 3 (OAT3; SLC22A8): genetic variation and functional genomics. Am. J. Physiol. Renal. Physiol. 2006, 290:905-912.
56. Dickinson D.A., Forman H.J. Cellular glutathione and thiols metabolism. Biochem. Pharmacol. 2002, 64:1019-1026.
57. Liu J., Lei D., Waalkes M.P., Beliles R.P., Morgan D.L. Genomic analysis of the rat lung following elemental mercury vapor exposure. Toxicol. Sci. 2003, 74:174-181.
58. 2-treated tubular MDCK cells. Toxicology 2005, 206:137-151.
59. Stacchiotti A., Morandini F., Bettoni F., Schena I., Lavazza A., Grigolato P.G., Apostoli P., Rezzani R., Aleo M.F. Stress proteins and oxidative damage in a renal derived cell line exposed to inorganic mercury and lead. Toxicology 2009, 264:215-224.
60. Dierickx P.J. Urinary gamma-glutamyl transferase as a specific marker for mercury after heavy metal treatment of rats. Toxicol. Lett. 1980, 6:235-238.
61. Woods J.S., Ellis M.E. Up-regulation of glutathione synthesis in rat kidney by methyl mercury: relationship to mercury-induced oxidative stress. Biochem. Pharmacol. 1995, 50:1719-1724.
62. Cookson M.R., Pentreath V.W. Protective roles of glutathione in the toxicity of mercury and cadmium compounds to C6 glioma cells. Toxicol. In Vitro 1996, 10:257-264.
63. Brambila E., Liu J., Morgan D.L., Beliles R.P., Waalkes M.P. Effect of mercury vapor exposure on metallothionein and glutathione s-transferase gene expression in the kidney of nonpregnant, pregnant, and neonatal rats. J. Toxicol. Environ. Health A 2002, 65:1273-1288.
64. Carvalho M.C., Nazari E.M., Farina M., Muller Y.M.R. Behavioral, morphological, and biochemical changes after in ovo exposure to methylmercury in chicks. Toxicol. Sci. 2008, 106:180-185.
65. Toyama T., Sumi D., Shinkai Y., Yasutake A., Taguchi K., Tong K.I., Yamamoto M., Kumagai Y. Cytoprotective role of Nrf2/Keap1 system in methylmercury toxicity. Biochem. Biophys. Res. Commun. 2007, 363:645-650.
66. Thompson S.A., White C.C., Krejsa C.M., Eaton D.L., Kavanagh T.J. Modulation of glutathione and glutamate-l-cysteine ligase by methylmercury during mouse development. Toxicol. Sci. 2000, 57:141-146.
67. Stringari J., Nunes A.K.C., Franco J.L., Bohrer D., Garcia S.C., Dafre A.L., Milatovic D., Souza D.O., Rocha J.B.T., Aschner M., Farina M. Prenatal methylmercury exposure hampers glutathione antioxidant system ontogenesis and causes long-lasting oxidative stress in the mouse brain. Toxicol. Appl. Pharmacol. 2008, 227:147-154.
68. Kobal A.B., Prezelj M., Horvat M., Krsnik M., Gibicar D., Osredkar J. Glutathione level after long-term occupational elemental mercury exposure. Environ. Res. 2008, 107:115-123.
69. Forgione M.A., Weiss N., Heydrick S., Cap A., Klings E.S., Bierl C., Eberhardt R.T., Farber H.W., Loscalzo J. Cellular glutathione peroxidase deficiency and endothelial dysfunction. Am. J. Physiol. Heart Circ. Physiol. 2002, 282:1255-1261.
70. Ristoff E., Larsson A. Inborn errors in the metabolism of glutathione. Orphanet J. Rare Dis. 2007, 2:16.
71. Hayes J.D., Flanagan J.U., Jowsey I.R. Glutathione transferases. Annu. Rev. Pharmacol. 2005, 45:51-88.
72. Ballatori N., Wang W., Lieberman M. Accelerated methylmercury elimination in gamma-glutamyl transpeptidase-deficient mice. Am. J. Pathol. 1998, 152:1049-1055.
73. Nichenametla S.N., Ellison I., Calcagnotto A., Lazarus P., Muscat J.E., Richie J.P. Functional significance of the GAG trinucleotide-repeat polymorphism in the gene for the catalytic subunit of γ-glutamylcysteine ligase. Free Radic. Biol. Med. 2008, 45:645-650.
74. Koide S., Kugiyama K., Sugiyama S., Nakamura S., Fukushima H., Honda O., Yoshimura M., Ogawa H. Association of polymorphism in glutamate-cysteine ligase catalytic subunit gene with coronary vasomotor dysfunction and myocardial infarction. J. Am. Coll. Cardiol. 2003, 41:539-545.
75. Nakamura S., Kugiyama K., Sugiyama S., Miyamoto S., Koide S., Fukushima H., Honda O., Yoshimura M., Ogawa H. Polymorphism in the 5'-flanking region of human glutamate-cysteine ligase modifier subunit gene is associated with myocardial infarction. Circulation 2002, 105:2968-2973.
76. Hu X., Xia H., Srivastava S.K., Herzog C., Awasthi Y.C., Ji X., Zimniak P., Singh S.V. Activity of four allelic forms of glutathione S-transferase hGSTP1-1 for diol epoxides of polycyclic aromatic hydrocarbons. Biochem. Biophys. Res. Commun. 1997, 238:397-402.
77. Johansson A.S., Stenberg G., Widersten M., Mannervik B. Structure-activity relationships and thermal stability of human glutathione transferase P1-1 governed by the H-site residue 105. J. Mol. Biol. 1998, 278:687-698.
78. Zimniak P., Nanduri B., Pikula S., Bandorowicz-Pikula J., Singhal S.S., Srivastava S.K., Awasthi S., Awasthi Y.C. Naturally occurring human glutathione-S-transferase GSTP1-1 isoforms with isoleucine and valine in position 104 differ in enzymic properties. Eur. J. Biochem. 1994, 224:893-899.
79. Morel F., Rauch C., Coles B., Le Ferrec E., Guillouzo A. The human glutathione transferase alpha locus: genomic organization of the gene cluster and functional characterization of the genetic polymorphism in the hGSTA1 promoter. Pharmacogenet. 2002, 12(4):277-286.
80. Gundacker C., Wittmann K.J., Kukuckova M., Komarnicki G., Hikkel I., Gencik M. Genetic background of lead and mercury metabolism in a group of medical students in Austria. Environ. Res. 2009, 109:786-796.
81. Custodio H.M., Broberg K., Wennberg M., Jansson J.H., Vessby B., Hallmans G., Stegnayr B., Skerfving S. Polymorphisms in glutathione-related genes affect methylmercury retention. Arch. Environ. Health 2004, 59:588-595.
82. Custodio H.M., Harari R., Gerhardsson L., Skerfving S., Broberg K. Genetic influences on the retention of inorganic mercury. Arch. Environ. Occup. Health 2005, 60:17-23.
83. Klautau-Guimarães M., DAscenção R., Caldart F.A., Grisolia C.K., Souza J., Barbosa A.C., Cordeiro C.M.T., Ferrari I. Analysis of genetic susceptibility to mercury contamination evaluated through molecular biomarkers in at-risk Amazon Amerindian populations. Genet. Mol. Biol. 2005, 28:827-832.
84. Schläwicke Engström K., Strömberg U., Lundh T., Johansson I., Vessby B., Hallmans G., Skerfving S., Broberg K. Genetic variation in glutathione-related genes and body burden of methylmercury. Environ. Health Persp. 2008, 116:734-739.
85. Aschner M., Syversen T., Souza D.O., Rocha J.B.T. Metallothioneins: mercury species-specific induction and their potential role in attenuating neurotoxicity. Exp. Biol. Med. 2006, 231:1468-1473.
86. Coyle P., Philcox J.C., Carey L.C., Rofe A.M. Metallothionein: the multipurpose protein. Cell. Mol. Life Sci. 2002, 59:1-21.
87. Sato M., Kondoh M. Recent studies on metallothionein: protection against toxicity of heavy metals and oxygen free radicals. Tohoku J. Exp. Med. 2002, 196:9-22.
88. Penkowa M. Metallothioneins are multipurpose neuroprotectants during brain pathology. FEBS J. 2006, 273:1857-1870.
89. Kramer K.K., Zoelle J.T., Klaassen C.D. Induction of metallothionein mRNA and protein in primary murine neuron cultures. Toxicol. Appl. Pharmacol. 1996, 141:1-7.
90. Kramer K.K., Liu J., Choudhuri S., Klaassen C.D. Induction of metallothionein mRNA and protein in murine astrocyte cultures. Toxicol. Appl. Pharmacol. 1996, 136:94-100.
91. Rodilla V., Miles A.T., Jenner W., Hawksworth G.M. Exposure of cultured human proximal tubular cells to cadmium, mercury, zinc and bismuth: toxicity and metallothionein induction. Chem. Biol. Interact. 1998, 115:71-83.
92. Beattie J.H., Owen H.L.H., Wallace S.M., Arthur J.R., Kwun I.S., Hawksworth G.M., Wallace H.M. Metallothionein overexpression and resistance to toxic stress. Toxicol. Lett. 2005, 157:69-78.
93. Peixoto N.C., Serafim M.A., Flores E.M.M., Bebianno M.J., Pereira M.E. Metallothionein, zinc, and mercury levels in tissues of young rats exposed to zinc and subsequently to mercury. Life Sci. 2007, 81:1264-1271.
94. Bourdineaud J.P., Bellance N., Bénard G., Brèthes D., Fujimura M., Gonzalez P., Marighetto A., Maury-Brachet R., Mormède C., Pédron V., Philippin J.N., Rossignol R., Rostène W., Sawada M., Laclau M. Feeding mice with diets containing mercury contaminated fish flesh from French Guiana: a model for the mercurial intoxication of the Wayana Amerindians. Environ. Health 2008, 7:53.
95. Kurisaki E., Sato M., Asano S., Gunji H., Mochizuki M., Odajima H., Wakasa H., Satoh H., Hiraiwa K. Insufficient metallothionein synthesis in the lung and kidney in human acute inorganic mercury poisoning. J. Health Sci. 1999, 45:309-317.
96. Yoshida M., Watanabe C., Satoh M., Yasutake A., Sawada M., Ohtsuka Y., Akama Y., Tohyama C. Susceptibility of metallothionein-null mice to the behavioral alterations caused by exposure to mercury vapor at human-relevant concentration. Toxicol. Sci. 2004, 80:69-73.
97. Yoshida M., Satoh M., Shimada A., Yamamoto E., Yasutake A., Tohyama C. Maternal-to-fetus transfer of mercury in metallothionein-null pregnant mice after exposure to mercury vapor. Toxicology 2002, 175:215-222.
98. Shimada A., Yamamoto E., Morita T., Yoshida M., Suzuki J.S., Satoh M., Tohyama C. Ultrastructural demonstration of mercury granules in the placenta of metallothionein-null pregnant mice after exposure to mercury vapor. Toxicol. Pathol. 2004, 32:519-526.
99. Giacconi R., Muti E., Malavolta M., Cipriano C., Costarelli L., Bernardini G., Gasparini N., Mariani E., Saba V., Boccoli G., Mocchegiani E. The +838C/G MT2A polymorphism, metals, and the inflammatory/immune response in carotid artery stenosis in elderly people. Mol. Med. 2007, 13:388-395.
100. Leslie E.M., Deeley R.G., Cole S.P.C. Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defens. Toxicol. Appl. Pharmacol. 2005, 204:216-237.
101. Kim S.H., Bark H., Choi C.H. Mercury induces multidrug resistance-associated protein gene through p38 mitogen-activated protein kinase. Toxicol. Lett. 2005, 155:143-150.
102. Ballatori N., Krance S.M., Marchan R., Hammond C.L. Plasma membrane glutathione transporters and their roles in cell physiology and pathophysiology. Mol. Aspects Med. 2009, 30:13-28.
103. +. Biochem. Biophys. Res. Commun. 2006, 351:719-725.
104. Leslie E.M., Deeley R.G., Cole S.P.C. Toxicological relevance of the multidrug resistance protein 1, MRP1 (ABCC1) and related transporters. Toxicology 2001, 167:3-23.
105. Ballatori N., Hammond C.L., Cunningham J.B., Krance S.M., Marchan R. Molecular mechanisms of reduced glutathione transport: role of the MRP/CFTR/ABCC and OATP/SLC21A families of membrane proteins. Toxicol. Appl. Pharm. 2005, 204:238-255.
106. Madejczyk M.S., Aremu D.A., Simmons-Willis T.A., Clarkson T.W., Ballatori N. Accelerated urinary excretion of methylmercury following administration of its antidote N-acetylcysteine requires Mrp2/Abcc2, the apical multidrug resistance-associated protein. J. Pharmacol. Exp. Ther. 2007, 322:378-384.
107. Sugawara N., Lai Y.R., Sugaware C., Arizono K. Decreased hepatobiliary secretion of inorganic mercury, its deposition and toxicity in the Eisai hyperbilirubinemic rat with no hepatic canalicular organic anion transporter. Toxicology 1998, 126:23-31.
108. Schinkel A.H., Mayer U., Wagenaar E., Mol C.A.A.M., van Deemter L., Smit J.J.M., van der Valk M.A., Voordouw A.C., Spits H., van Tellingen O., Zijlmans J.M.J.M., Fibbe W.E., Borst P. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc. Natl. Acad. Sci. U.S.A. 1997, 94:4028-4033.
109. Kusuhara H., Sugiyama Y. Efflux transport systems for drugs at the blood-brain barrier and blood-cerebrospinal fluid barrier (part 2). Drug Discov. Today 2001, 6:206-212.
110. Allen D., Brinkhuis R.F., van Deemter L., Wijnholds J., Schinkel A.H. Extensive contribution of the multidrug transporters P-glycoprotein and Mrp1 to basal drug resistance. Cancer Res. 2000, 60:5761-5766.
111. Liu J., Liu Y., Powell D.A., Waalkes M.P., Klaassen C.D. Multidrug-resistance mdr1a/1b double knockout mice are more sensitive than wild type mice to acute arsenic toxicity, with higher arsenic accumulation in tissues. Toxicology 2002, 170:55-62.
112. Conseil G., Deeley R.G., Cole S.P.C. Polymorphisms of MRP1 (ABCC1) and related ATP-dependent drug transporters. Pharmacogenet. Genom. 2005, 15:523-533.
113. Huang Y. Pharmacogenetics/genomics of membrane transporters in cancer chemotherapy. Cancer Metastasis. Rev. 2007, 26:183-201.
114. Letourneau I.J., Deeley R.G., Cole S.P.C. Functional characterization of non-synonymous single nucleotide polymorphisms in the gene encoding human multidrug resistance protein 1 (MRP1/ABCC1). Pharmacogenet. Genom. 2005, 15:647-657.
115. Brinkmann U., Eichelbaum M. Polymorphisms in the ABC drug transporter gene MDR1. Pharmocogenomic J. 2001, 1:59-64.
116. Woodahl E.L., Yang Z., Bui T., Shen D.D., Ho R.J.Y. Multidrug resistance gene G1199A polymorphism alters efflux transport activity of P-glycoprotein. J. Pharmacol. Exp. Ther. 2004, 310:1199-1207.
117. Hitzl M., Schaeffeler E., Hocher B., Slowinski T., Halle H., Eichelbaum M., Kaufmann P., Fritz P., Fromm M.F., Schwab M. Variable expression of P-glycoprotein in the human placenta and its association with mutations of the multidrug resistance 1 gene (MDR1, ABCB1). Pharmacogenet. Genom. 2004, 14:309-318.
118. Tanabe M., Ieiri I., Nagata N., Inoue K., Ito S., Kanamori Y., Takahashi M., Kurata Y., Kigawa J., Higuchi S., Terakawa N., Otsubo K. Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J. Pharmacol. Exp. Ther. 2001, 297:1137-1143.
119. Gerloff T. Impact of genetic polymorphisms in transmembrane carrier-systems on drug and xenobiotic distribution. N.-S. Arch. Pharmacol. 2004, 369:69-77.
120. Kimchi-Sarfaty C., Oh J.M., Kim I.W., Sauna Z.E., Calcagno A.M., Ambudkar S.V., Gottesman M.M. A " silent" polymorphism in the MDR1 gene changes substrate specificity. Science 2007, 315:525-528.
121. Papanikolaou N.C., Hatzidaki E.G., Belivanis S., Tzanakakis G.N., Tsatsakis A.M. Lead toxicity update. A brief review. Med. Sci. Monit. 2005, 11:329-336.
122. Deane R., Bradbury M.W.B. Transport of lead-203 at the blood-brain barrier during short cerebrovascular perfusion with saline in the rat. J. Neurochem. 1990, 54:905-914.
123. Onalaja A.O., Claudio L. Genetic susceptibility to lead poisoning. Environ. Health Persp. 2000, 108:23-28.
124. Cheong J.H., Bannon D., Olivi L., Kim Y., Bressler J. Different mechanisms mediate uptake of lead in a rat astroglial cell line. Toxicol. Sci. 2004, 77:334-340.
125. Bannon D.I., Abounader R., Lees P.S.J., Bressler J.P. Effect of DMT1 knockdown on iron, cadmium, and lead uptake in Caco-2 cells. Am. J. Physiol. Cell Physiol. 2003, 284:44-50.
126. Theppeang K., Schwartz B., Lee B.K., Lustberg M.E., Silbergeld E., Kelsey K.T., Parsons P.J., Todd A.C. Associations of patella lead with polymorphisms in the vitamin D receptor, δ-aminolevulinic acid dehydratase and endothelial nitric oxide synthase genes. J. Occup. Environ. Med. 2004, 46:528-537.
127. Weaver V.M., Lee B.K., Todd A.C., Ahn K.D., Shi W., Jaar B.G., Kelsey K.T., Lustberg M.E., Silbergeld E.K., Parsons P.J., Wen J., Schwartz B.S. Effect modification by [delta]-aminolevulinic acid dehydratase, vitamin D receptor, and nitric oxide synthase gene polymorphisms on associations between patella lead and renal function in lead workers. Environ. Res. 2006, 102:61-69.
128. Schwartz B.S., Lee B.K., Lee G.S., Stewart W.F., Simon D., Kelsey K., Todd A.C. Associations of blood lead, dimercaptosuccinic acid-chelatable lead, and tibia lead with polymorphisms in the vitamin D receptor and [delta]-aminolevulinic acid dehydratase genes. Environ. Health Persp. 2000, 108:949-954.
129. Uitterlinden A.G., Fang Y., Van Meurs J.B.J., Pols H.A.P., Van Leeuwen J.P.T.M. Genetics and biology of vitamin D receptor polymorphisms. Gene 2004, 338:143-156.
130. Kelleher T., Ryan E., Barrett S., O'Keane C., Crowe J. DMT1 genetic variability is not responsible for phenotype variability in hereditary hemochromatosis. Blood Cell Mol. Dis. 2004, 33:35-39.
131. Barton J.C., Patton M.A., Edwards C.Q., Griffen L.M., Kushner J.P., Meeks R.G., Leggett R.W. Blood lead concentrations in hereditary hemochromatosis. J. Lab Clin. Med. 1994, 124:193-198.
132. Hopkins M.R., Ettinger A.S., Hernández-Avila M., Schwartz J., Téllez-Rojo M.M., Lamadrid-Figueroa H., Bellinger D., Hu H., Wright R.O. Variants in iron metabolism genes predict higher blood lead levels in young children. Environ. Health Persp. 2008, 116:1261-1266.
133. Wang F.T., Hu H., Schwartz J., Weuve J., Spiro A.S., Sparrow D., Nie H., Silverman E.K., Weiss S.T., Wright R.O. Modifying effects of the HFE polymorphisms on the association between lead burden and cognitive decline. Environ. Health Persp. 2007, 115:1210-1215.
134. Wright R.O., Silverman E.K., Schwartz J., Tsaih S.W., Senter J., Sparrow D., Weiss S.T., Aro A., Hu H. Association between hemochromatosis genotype and lead exposure among elderly men: the normative aging study. Environ. Health Persp. 2004, 112:746-750.
135. Akesson A., Stal P., Vahter M. Phlebotomy increases cadmium uptake in hemochromatosis. Environ. Health Persp. 2000, 108:289-291.
136. Wright L.S., Kornguth S.E., Oberley T.D., Siegel F.L. Effects of lead on glutathione s-transferase expression in rat kidney: a dose-response study. Toxicol. Sci. 1998, 46:254-259.
137. Daggett D.A., Oberley T.D., Nelson S.A., Wright L.S., Kornguth S.E., Siegel F.L. Effects of lead on rat kidney and liver: GST expression and oxidative stress. Toxicology 1998, 128:191-206.
138. Bokara K.K., Blaylock I., Denise S.B., Bettaiya R., Rajanna S., Yallapragada P.R. Influence of lead acetate on glutathione and its related enzymes in different regions of rat brain. J. Appl. Toxicol. 2009, 29:452-458.
139. Hunaiti A., Soud M., Khalil A. Lead concentration and the level of glutathione, glutathione S-transferase, reductase and peroxidase in the blood of some occupational workers from Irbid City, Jordan. Sci. Total Environ. 1995, 170:95-100.
140. Kasperczyk S., Kasperczyk A., Ostalwska A., Dziwisz M., Birkner E. Activity of glutathione peroxidase, glutathione reductase, and lipid peroxidation in erythrocytes in workers exposed to lead. Biol. Trace Elem. Res. 2004, 102:61-72.
141. Glahn F., Schmidt-Heck W., Zellmer S., Guthke R., Wiese J., Golka K., Hergenröder R., Degen G., Lehmann T., Hermes M., Schormann W., Brulport M., Bauer A., Bedawy E., Gebhardt R., Hengstler J., Foth H. Cadmium, cobalt and lead cause stress response, cell cycle deregulation and increased steroid as well as xenobiotic metabolism in primary normal human bronchial epithelial cells which is coordinated by at least nine transcription factors. Arch. Toxicol. 2008, 82:513-524.
142. Jurczuk M., Moniuszko-Jakoniuk J., Brzóska M.M. Involvement of some low-molecular thiols in the peroxidative mechanisms of lead and ethanol action on rat liver and kidney. Toxicology 2006, 219:11-21.
143. Qu W., Diwan B.A., Liu J., Goyer R.A., Dawson T., Horton J.L., Cherian M.G., Waalkes M.P. The Metallothionein-null phenotype is associated with heightened sensitivity to lead toxicity and an inability to form inclusion bodies. Am. J. Pathol. 2002, 160:1047-1056.
144. Montenegro M.F., Barbosa F., Sandrim V.C., Gerlach R.F., Tanus-Santos J.E. A polymorphism in the delta-aminolevulinic acid dehydratase gene modifies plasma/whole blood lead ratio. Arch. Toxicol. 2006, 80:394-398.
145. Bellinger D., Wu H., Titlebaum L., Needleman H.L. Attentional correlates of dentin and bone lead levels in adolescents. Arch. Environ. Health 1994, 49:98-105.
146. Glaeser H., Coblenz A., Kruczek R., Ruttke I., Ebert-Jung A., Wolf K. Glutathione metabolism and heavy metal detoxification in Schizosaccharomyces pombe. Curr. Genet. 1991, 19:207-213.
147. Alexander J., Aaseth J., Mikalsen A. Excretion of lead in rat bile-the role of glutathione. Acta Pharmacol. Toxicol. 1986, 59:486-489.
148. Song W.Y., Sohn E.J., Martinoia E., Lee Y.J., Yang Y.Y., Jasinski M., Forestier C., Hwang I., Lee Y. Engineering tolerance and accumulation of lead and cadmium in transgenic plants. Nat. Biotechnol. 2003, 21:914-919.
149. Gueldry O., Lazard M., Delort F., Dauplais M., Grigoras I., Blanquet S., Plateau P. Ycf1p-dependent Hg(II) detoxification in Saccharomyces cerevisiae. Eur. J. Biochem. 2003, 270:2486-2496.
150. Whitfield J.B., Dy V., McQuilty R., Zhu G., Montgomery G.W., Ferreira M.A.R., Duffy D.L., Neale M.C., Heijmans B.T., Heath A.C., Martin N.G. Evidence of genetic effects on blood lead concentration. Environ. Health Perspect. 2007, 115:1224-1230.